Compare Twist Bioscience Corp (TWST) vs Workday Inc (WDAY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Twist Bioscience Corp vs Workday Inc — how do they compare? Twist Bioscience Corp trades at $125.52 (market cap $8.42B), while Workday Inc trades at $186.52 (market cap $44.89B). The key difference: Workday Inc is far larger — about 5.3× Twist Bioscience Corp's market cap, and Twist Bioscience Corp is trading nearer its 52-week high, Workday Inc nearer its low. Which is the better fit depends on your goals.
| TWST | WDAY | |
|---|---|---|
Market Cap | $8.42B | $44.89B |
Sector | Health | Technology |
52-Week High | $153.10 | $247.69 |
52-Week Low | $24.16 | $112.55 |
Enterprise Value | $8.35B | $45.26B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Twist Bioscience (TWST) trades at $128.06, up 2.68% today, but remains below the analyst consensus price target of $106.14. The stock shows mixed technical signals with bearish overall momentum but bullish moving averages. Fundamentally, the company continues to report losses with a net income margin of -31.66% despite 23% revenue growth in Q3 2026. Recent news highlights AI-driven optimism and institutional buying interest.
TWST presents a high-risk growth story with strong analyst support (79% buy ratings) but persistent profitability challenges. The stock's valuation appears stretched with P/S of 18.09 and P/B of 18.89. Key catalysts include AI drug discovery partnerships and path to EBITDA breakeven, while risks include cash burn and competitive pressures in biotech.
Workday (WDAY) trades at $186.28, down 4.86% on the day, but maintains a bullish technical signal with strong moving average support. The company reported Q2 2026 EPS of $2.75, beating estimates of $2.61, marking the third consecutive quarterly beat. Revenue growth remains robust, projected to reach $10.2B in 2026, while net income margin improved to 12.32%. Recent news highlights AI adoption gains and a leadership position in cloud HCM suites.
The outlook is positive with analyst consensus favoring a Buy rating and a $204.52 price target, implying potential upside. Key opportunities include AI-driven subscription growth and expanding margins, but risks involve high valuation multiples and competitive pressures in the enterprise software space. Execution on AI initiatives and sustained profitability are critical for continued stock appreciation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →About Workday Inc
Workday is a software company that offers human capital management, or HCM, financial management, and business planning solutions. Known for being a cloud-only software provider, Workday is headquartered in Pleasanton, California. Founded in 2005, Workday now employs over 12,000 employees.
Read more on WDAY →
